Mutation-drug sensitivity data resource (MDSDR):a comprehensive resource for studying and addressing drug resistance

Graphical abstract

References

[1] Haider T, Pandey V, Banjare N, Gupta P N, Soni V . Drug resistance in cancer: mechanisms and tackling strategies. Pharmacological Reports, 2020, 72( 5): 1125–1151

[2] Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S . Drug resistance in cancer: an overview. Cancers, 2014, 6( 3): 1769–1792

[3] Wu F X, Wang F, Yang J F, Jiang W, Wang M Y, Jia C Y, Hao G F, Yang G F . AIMMS suite: a Web server dedicated for prediction of drug resistance on protein mutation. Briefings in Bioinformatics, 2020, 21( 1): 318–328

[4] Griffith M, Spies N C, Krysiak K, Mcmichael J F, Coffman A C, Danos A M, Ainscough B J, Ramirez C A, Rieke D T, Kujan L, Barnell E K, Wagner A H, Skidmore Z L, Wollam A, Liu C J, Jones M R, Bilski R L, Lesurf R, Feng Y Y, Shah N M, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell K M, Spies G C, Graubert A P, Gangavarapu K, Eldred J M, Larson D E, Walker J R, Good B M, Wu C, Su A I, Dienstmann R, Margolin A A, Tamborero D, Lopez-Bigas N, Jones S J M, Bose R, Spencer D H, Wartman L D, Wilson R K, Mardis E R, Griffith O L . CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics, 2017, 49( 2): 170–174

[5] Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn C F, Whaley R, Klein T E . An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 2021, 110( 3): 563–572

[6] Shen Y, Zhang Y, Xue W, Yue Z . dbMCS: a database for exploring the mutation markers of anti-cancer drug sensitivity. IEEE Journal of Biomedical and Health Informatics, 2021, 25( 11): 4229–4237

[7] Behan F M, Iorio F, Picco G, et al. Prioritization of Cancer therapeutic targets using CRISPR-Cas9 screens. Nature, 2019, 568: 511–516

[8] Yang W, Soares J, Greninger P, Edelman E J, Lightfoot H, Forbes S, Bindal N, Beare D, Smith J A, Thompson I R, Ramaswamy S, Futreal P A, Haber D A, Stratton M R, Benes C, Mcdermott U, Garnett M J . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2012, 41( D1): D955–D961

[9] Liu X, Shen T, Mooers B H M, Hilberg F, Wu J . Drug resistance profiles of mutations in the RET kinase domain. British Journal of Pharmacology, 2018, 175( 17): 3504–3515

[10] Hauser K, Negron C, Albanese S K, Ray S, Steinbrecher T, Abel R, Chodera J D, Wang L . Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Communications Biology, 2018, 1: 70

[11] Yang Z, Ye Z, Qiu J, Feng R, Li D, Hsieh C, Allcock J, Zhang S . A mutation-induced drug resistance database (MdrDB). Communications Chemistry, 2023, 6( 1): 123

[12] UniProt Consortium . UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Research, 2023, 51( D1): D523–D531

Acknowledgements

This work was supported by grants from STI 2030—Major Projects (No. 2022ZD0209100), the National Natural Science Foundation of China (Grant Nos. 81971292, 82150610506, and 62372099), the Natural Science Foundation of Shanghai (No. 21ZR1428600), the Medical-Engineering Cross Foundation of Shanghai Jiao Tong University (Nos. YG2022ZD026 and YG2023ZD27), SJTU Trans-med Awards Research (No. 20220103), and Shanghai Clinical Research Center for Mental Health (19MC1911100).

Competing interests

The authors declare that they have no competing interests or financial conflicts to disclose.

Electronic supplementary material

Supplementary material is available in the online version of this article at journal.hep.com.cn and link.springer.com.

RIGHTS & PERMISSIONS

2025 Higher Education Press